The prostate originates from the urogenital sinus (UGS), and cell lineage analysis demonstrates that the UGS is derived from the endoderm and gives rise to the entire urethra \[[@CR1]\]. The UGS is partitioned into two parts, the urogenital sinus epithelium (UGE) and the surrounding urogenital sinus mesenchyme (UGM). Recombinant tissue experiments indicate that the interaction between the UGM and the UGE is sufficient to generate a well-developed prostate \[[@CR2], [@CR3]\]. It was known very early that the development of the prostate is under the control of androgens, which are secreted from the testes \[[@CR4]\]. The fetal testes start to produce testosterone at approximately 9 weeks of gestation in humans and at E13--14 in mice, and testosterone is further converted into dihydrotestosterone, a more effective androgen, by 5α-reductase \[[@CR5]\]. The androgen receptor (AR) pathway plays an extremely important role in the induction of the prostate \[[@CR6]\].

Epithelial prostatic budding occurs at approximately 9--10 weeks of gestation in humans \[[@CR7]\] and at E17.5 in mice \[[@CR8]\] (Fig. [1](#Fig1){ref-type="fig"}). FOXA1, an important pioneer gene in endoderm-derived epithelial cells, is highly expressed in prostate epithelial cells \[[@CR9]\]. FOXA1 can interact with closed chromatin and loosen nucleosomes as a pioneer factor, therefore allowing AR to bind to the DNA \[[@CR10]\]. More importantly, it has been demonstrated that FOXA1 mutations disturb prostate differentiation \[[@CR11]\]. In addition to AR, NKX3-1 is indispensable in prostate specification. NKX3-1 starts to be expressed 2 days prior to prostatic budding, suggesting that NKX3-1 may define the initiation of prostate organogenesis. Moreover, NKX3-1 uniquely marks the prostate epithelium and is not detected in other tissues of the male urogenital system. Functionally, a defect in NKX3-1 alters prostate development in mice \[[@CR12]\]. In addition, the combination of AR, FOXA1, and NKX3-1 is identified as a driver for prostate organogenesis by a computational system approach named the Master Regulator Inference algorithm \[[@CR13]\]. Moreover, these master regulators are used to reprogram induced epithelial cells derived from mouse fibroblasts into prostate tissue. These reprogrammed prostate-like cells exhibited appropriate histological and molecular properties of the prostate after grafting into a mouse model \[[@CR13]\]. Fig. 1Major events during prostatic development and the respective developmental time in the mouse and human. Prostate originates from the progenitors within UGS, which goes through budding and branching morphogenesis, and eventually matures to the prostatic epithelium. wk, weeks after gestation; E, embryonic day; P, postnatal day

The next key events after prostatic budding are ductal outgrowth and branching morphogenesis. Budding starts during late fetal development, and the most prominent bud outgrowth occurs during the first two postnatal weeks in rodents \[[@CR14]\]. The elongation and branching morphogenesis of human prostatic buds starts at 11 weeks of gestation and peaks at 16 weeks of gestation. In contrast to that in rodents, most of the prostate epithelium in humans is in the form of canalized ducts undergoing secretory cytodifferentiation before birth \[[@CR15]\]. The theory of branching and annihilating random walks (BARWs) describes a process whereby the active tips elongate in all directions to randomly form ducts; ducts can branch through stochastic tip bifurcation at any moment or terminate when the tips meet with an existing duct \[[@CR16]\]. The duct network can greatly maximize the exchange surface between the prostate epithelium and lumen. This model explains duct network heterogeneity and its spatiotemporal pattern. The FGF10/FGFR2IIIB interaction is reported to upregulate the expression of SHH and BMP7, which together contribute to duct branching morphogenesis. Additionally, SHH can downregulate FGF10 expression as a negative feedback loop and upregulate BMP4 expression, which controls duct elongation \[[@CR17]\]. In addition, PI3K/mTOR signaling is required for prostate epithelial invasion and therefore regulates prostatic branching morphogenesis \[[@CR18]\].

AR/WNT/BMP signaling pathways in prostate development {#Sec1}
=====================================================

AR is the most studied signal in both prostate development and prostate cancer. AR is recognized as a nuclear receptor but only enters the nucleus upon binding with androgen hormones and then exerts its function as a transcription factor \[[@CR19]\]. Immediately after sex determination, dihydrotestosterone converted from testosterone by 5α-reductase binds to AR to activate the expression of NKX3-1, FOXA1, PSA, and other prostatic genes, therefore promoting prostate budding, branching morphogenesis, and maturation \[[@CR20]\]. Testicular feminization mutant (Tfm) mice carrying a natural defect in the AR locus show an absence of prostatic buds, indicating the essential role of AR \[[@CR21]\]. Conditional deletion of AR in both stromal fibroblasts and smooth muscle cells can impair branching morphogenesis in a mouse model \[[@CR22]\], suggesting an additional critical role in subsequent ductal branching morphogenesis. In addition, AR and circulating androgens are both abundant in the UGS of male mice, while only the level of circulating androgens is quite low in females, which suggests that androgens play a priming role. In support of this notion, exogenous dihydrotestosterone can induce prostatic budding in the UGS of both wild-type female mice and Tfm male mice \[[@CR23]\]. Androgen-independent signals are involved in prostate initiation and budding. The WNT signaling pathway is one of the most important signaling pathways playing a dominant role in cell fate determination \[[@CR24]\]. The canonical WNT signaling pathway depends on the translocation of the β-catenin protein (encoded by the CTNNB1 gene), and nuclear β-catenin forms a complex with members of the TCF/LEF family to activate the transcription of WNT target genes \[[@CR25]\]. The WNT signaling pathway regulates prostate specification and subsequent prostatic budding and epithelial branching morphogenesis as well as prostate stem cell self-renewal. Several WNT ligands and the WNT upstream regulator R-spondin 3 are present in the lower urogenital tract during prostate development and are more abundant in the male UGS than in the female UGS \[[@CR26]\]. The β-catenin and WNT/β-catenin-responsive downstream genes Axin2 and Lef1 are highly expressed in the prostatic bud epithelium and colocalize with NKX3-1. Moreover, treatment of UGS explant cultures with a WNT antagonist, such as DKK1, not only decreases the number of prostatic buds but also inhibits NKX3-1 expression, indicating critical roles for WNT/β-catenin during prostate specification and bud formation \[[@CR27]\]. Conditional deletion of β-catenin in the E15.5 mouse UGS prevents prostatic differentiation and bud formation. Interestingly, pretreatment of the mouse E15.5 UGS with dihydrotestosterone for 24 h can result in rudimentary bud formation, even after inducing β-catenin deletion by tamoxifen treatment \[[@CR27]\]. This indicates that β-catenin is required for initiating prostate differentiation but not for subsequent prostate gland formation. Supporting this conclusion, the specific deletion of β-catenin in adult luminal epithelial cells in the prostate gland in Probasin-Cre mice does not affect glandular homeostasis \[[@CR28]\]. However, treatment of cultured postnatal rat ventral prostates with either the WNT agonist WNT3A or WNT antagonist DKK1 leads to a significantly reduced number of branches \[[@CR29]\], suggesting a delicate dosing effect of WNT signaling on prostatic epithelial branching morphogenesis. In addition, the noncanonical WNT/calcium pathway, in which noncanonical WNT ligands such as WNT4, WNT5A, and WNT11 mediate the induction of intracellular Ca2+ transients to activate the Ca2+-sensitive kinases CAMK2 and PKC \[[@CR30]\], also plays a role in building a unique branch pattern during prostate branching morphogenesis. WNT5A is mainly expressed at the distal tips, and ex vivo experiments show that WNT5A treatment does not affect prostate bud initiation but regulates the size and number of buds \[[@CR31]\].

The BMP signaling pathways is necessary for prostate budding/BMP signaling pathway is also critically involved in prostate development. BMP4 is highly expressed in the male UGS from E14 to birth. Exogenous BMP4 can inhibit prostate ductal budding in a dose-dependent manner, and in BMP4 haplo-insufficient adult mice, the prostate contains an increased number of duct tips \[[@CR32]\]. These data demonstrate that the BMP signal inhibits prostate ductal budding to ensure an appropriate number of ductal tips for normal prostate development. In addition, activin A is weakly expressed during development, but its expression is upregulated in the prostatic epithelium during puberty. Follistatin and activin receptors are expressed throughout the prostatic epithelium. Functionally, activin A can inhibit prostatic branching in prostate organ cultures, but follistatin, an activin-binding protein that inhibits TGFβ signaling, can increase branching in vitro \[[@CR33]\]. Taken together, these data suggest that the TGFβ/BMP signaling pathway negatively regulates prostatic ductal branching morphogenesis.

BMP signaling pathways synergistically determine prostate development/BMP signaling pathways synergistically determine prostate development (Fig. [2](#Fig2){ref-type="fig"}). Conditionally knocking out β-catenin in the UGS results in undetectable NKX3-1 expression, but AR is still highly expressed \[[@CR28]\]. These results indicate that prostate lineage specification depends on WNT/β-catenin signaling even when the AR signaling pathway is active. However, after the completion of prostate lineage commitment, prostate development can occur without the canonical WNT signaling pathway \[[@CR28]\]. Both ex vivo and tissue implantation experiments demonstrate that when AR is deleted in AXIN2-expressing mouse prostate cells, the formed prostates are relatively small and immature \[[@CR34]\]. This indicates the indispensable role for AR in WNT-responsive cells during all the stages of prostate development. In the prostate cancer cell line LNCaP, WNT3A treatment can promote AR binding to the promoter regions of WNT target genes such as MYC and CYCLIN D1; additionally, AR and β-catenin can be recruited to the promoter and enhancer regions of the AR target gene PSA \[[@CR35]\]. Another report also noted that WNT/β-catenin could increase AR expression through the binding of LEF1 to the promotor of AR \[[@CR36]\]. In addition, active WNT/β-catenin can activate BMP signaling in prostatic bud tips to inhibit inappropriate prostatic budding and together ensure the initiation of prostate development \[[@CR37]\]. β-catenin transcriptionally upregulates the expression of TGFβ2, TGFβ3, and BMP4 in prostate stromal cells, and the activated TGFβ pathway suppresses basal cell proliferation \[[@CR37], [@CR38]\]. The TGFβ and AR signaling pathways in the stroma can affect the WNT signaling pathway, which helps to limit prostatic regression \[[@CR39]\]. Therefore, a balance between the WNT and TGFβ/BMP signaling pathways is necessary for prostate budding. Fig. 2Crosstalk between key signal pathways during prostatic budding. AR signaling pathway activates canonical WNT signaling, which in turn activates the master regulator NKX3-1 to that drives prostatic budding from UGE. In addition, WNT signaling can directly promote AR signal or indirectly inhibit AR signal by activating BMP signal which inhibits AR and prostate ductal budding. AR/WNT/BMP work together to ensure an appropriate number of ductal tips for normal prostate development

Prostate lineage differentiation from pluripotent stem cells {#Sec2}
============================================================

Current knowledge on prostate development is mainly derived from rodent animal models and prostate cancer cell lines; however, there are significant differences between the human prostate and rodent prostate, such as differences in histology and morphology. Limited by the shortage of human prostate materials, especially embryonic specimens, a more widespread method is urgently required. Human pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), harbor the capacity to undergo multilineage differentiation to generate almost all cell types composing the body. Therefore, human pluripotent stem cells may provide a promising source to study human prostate development (Fig. [3](#Fig3){ref-type="fig"}). As early as 2006, a study by Taylor et al. showed that human ESCs are able to differentiate into the prostatic lineage by utilizing a co-transplantation assay \[[@CR40]\]. They constructed a hetero-species recombinant tissue composed of the mouse UGM or rat seminal vesicle mesenchyme and human ESCs under the renal capsule of immunodeficient mice and observed prostate-like tissue within 8--12 weeks. Key transcription factors such as AR and NKX3-1 and the epithelial cell markers P63, CK8, and CK18 were detected at 4 weeks, while a mature prostate that expressed prostate-specific antigen (PSA) and exhibited prostate layer structures appeared 8--12 weeks after grafting \[[@CR40]\]. However, this approach utilized co-culture and transplantation and was inefficient, hindering further mechanistic study and applications. Fig. 3Summary and proposal of prostate differentiation from human pluripotent stem cells. Human ESC/iPSC can respond to TGFβ signaling pathway to differentiate into definitive endoderm, from which there are two paths to generate prostate organoids: mimic the prostate development process (from definitive endoderm to hindgut stage by WNT and FGF signaling pathways, then to UGS by certain signals, and eventually to prostate organoids by AR and other signaling pathways; or direct to bladder urothelial cells by RA, and then transdifferentiate into prostate organoids

Prostate organogenesis is a stepwise process. The prostate arises from the UGS, which is a caudal extension of the endoderm-derived hindgut \[[@CR1]\]. It was demonstrated that definitive endoderm specification is mainly controlled by the NODAL/SMAD signaling pathway \[[@CR41]\]. Consistently, human ESCs can be efficiently differentiated into the definitive endoderm lineage upon activin A treatment in low-serum cultures \[[@CR42]\]. The endoderm germ layer is an undetermined sheet of cells, it forms a primitive tube and becomes regionally specified along the anterior-posterior axis later, and FGF signaling is necessary for establishing the posterior endoderm \[[@CR43]\]. In addition, high β-catenin activity is observed in the posterior endoderm and inhibits the foregut fate \[[@CR44]\]. Therefore, agonists of FGF and WNT signals are used to differentiate the definitive endoderm into CDX2-positive hindgut lineages \[[@CR45]\].

Although many achievements have been made in efficiently differentiating human ESCs/iPSCs into the definitive endoderm and hindgut, there are very few reports on the directed differentiation from the hindgut to the UGS and subsequently to the prostate lineage. The master signals of this process are still largely unknown, but some attempts have been made to elucidate this process. Inspired by the early success achieved in generating prostate lineage cells following co-transplantation of human ESCs and the rodent UGM \[[@CR40]\], Hepburn and colleagues first generated prostate-derived human iPSCs and differentiated iPSCs into the definitive endoderm. Then, the differentiated endoderm cells were cocultured with the UGM in vitro. They observed increased efficiency of prostatic epithelial differentiation \[[@CR46]\]. However, there are still many problems in directed prostatic differentiation requiring further exploration.

stem cells are capable of generating a range of differentiated/stem cells are capable of generating a range of differentiated cells, including prostate lineages \[[@CR3]\]. A tissue recombination experiment using the UGM with adult bladder epithelia suggests that the UGM can induce bladder epithelial cells to form a prostate through a trans-differentiation mechanism that requires stromal TGF-β signaling to mediate epithelial WNT activity \[[@CR47]\]. In addition, bladder urothelium differentiation from human ESC-derived endoderm has been successfully achieved in vitro. Kang and colleagues first generated bladder urothelial cells from human ESCs under serum- and feeder-free conditions with retinoic acid, and the bladder urothelial cells highly expressed urothelium-specific genes such as UPIB, UPII, UPIIIA, P63, and CK7 \[[@CR48]\]. This may represent an alternative approach to guide prostate generation from human ESCs/iPSCs (Fig. [3](#Fig3){ref-type="fig"}).

Prostate organoids {#Sec3}
==================

An organoid is an advanced technology that mimics the hallmarks, cell types, and even the structure and functions of real organs and hence provides an alternative in vitro model for developmental study and disease modeling \[[@CR49]\]. ESCs/iPSCs provide an ideal source to construct prostate organoids. Human ESC/iPSC-derived organoids can be used as powerful platforms in modeling human organ development and disease. For example, human gastric organoids have been generated in vitro from pluripotent stem cells through manipulation of the FGF, WNT, BMP, retinoic acid, and EGF signaling pathways as well as three-dimensional culture. Generated gastric organoids have been used to identify novel signals that regulate early endoderm patterning or to study the function of the transcription factor NEUROG3 in gastric endocrine cell differentiation. Moreover, human gastric organoids have been used to mimic the pathophysiological response of the gastric epithelium to *H. pylori*, which manifests the potential of these organoids in drug discovery and modeling the early stages of gastric disease and even cancer \[[@CR50]\]. Similar achievements have been made in studying human lung development during gestation, recapitulating fibrotic lung disease in vitro by introducing the mutation in HPS1 that causes an early-onset form of intractable pulmonary fibrosis \[[@CR51]\] and modeling colonic familial adenomatous polyposis, which identified geneticin as a promising drug for APC-mutant patients \[[@CR52]\].

Prostate organoids can be derived from pluripotent stem cells, prostatic progenitor cells, or primary prostate biopsy samples (Fig. [4](#Fig4){ref-type="fig"}). Based on the strategy that the R-spondin 1-based WNT-activation culture method allows long-term propagation of murine and human prostate epithelium, both basal and luminal populations have been demonstrated to contain bipotent progenitor cells, therefore making it possible to establish murine and human prostate organoids in vitro. Basal- or luminal-derived prostate organoids express AR, NKX3-1, and prostate epithelium layer markers including P63, CK5, and CK8 \[[@CR53]\]. Moreover, those organoids exhibit testosterone responsiveness upon dihydrotestosterone addition or withdrawal. Also, the Zeb1+ prostate epithelial cells are multipotent prostate basal stem cells that can self-renew and therefore capable of generating functional prostate organoids at the single-cell level \[[@CR54]\]. Prostate organoids derived from iPSCs were successfully generated using a co-culture technique with the urogenital sinus mesenchyme, and early prostate organoids can be generated within several weeks \[[@CR46]\]. Fig. 4Application overview of human prostate organoid technology. Prostate organoids can be generated from prostate primary tissues or tumor samples directly or derived from iPSC through somatic reprogramming, differentiation, and co-culture technology. Prostate organoids have wide application potentials and provide a valuable resource to study human development, model pathogenesis, and test drugs

Organoids can be used to study the functions of genes involved in prostate cancer initiation by gene editing \[[@CR55]\]. Genetic ablation studies reveal the indispensable role of Zeb1 in prostate development \[[@CR54]\]. In addition to normal prostate cells, a testosterone-responsive prostate organoid culture system derived from advanced prostate cancer tissue was developed to study prostate homeostasis and tumorigenesis \[[@CR56], [@CR57]\]. Recent research has demonstrated that prostate stromal cells can increase organoid formation efficiency and influence organoid branching morphogenesis via cell-cell contact and secrete soluble growth factors that may regulate branching \[[@CR58]\]. This system provides a powerful model to study the functions of developmental regulators or oncogenes, such as MYC and AKT1 \[[@CR55]\]. The high-throughput model can rapidly generate human prostate tissue ex vivo and in vitro, which makes it a better model for studying prostate development and disease than slow, inefficient, and laborious prostate organoids derived from primary cultures \[[@CR46]\] (Fig. [4](#Fig4){ref-type="fig"}).

Conclusion {#Sec4}
==========

In this review, we have briefly introduced prostate development and summarized the major signaling pathways involved in prostate development and differentiation (i.e., the AR, WNT, and TGF-β/BMP signaling pathways). To advance our understandings of human prostate development and prostatic disease, prostate organoids based on human pluripotent stem cells would be a promising and valuable tool with some challenges.
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